Prime Medicine

company

About

Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.

Details

Last Funding Type
Series A
Last Funding Money Raised
$115M
Industries
Biotechnology,Genetics,Life Science,Medical
Founded date
Jan 1, 2019
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:PRME
Legal Name
Prime Medicine, Inc.

Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.

It was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$490M
Prime Medicine has raised a total of $490M in funding over 2 rounds. Their latest funding was raised on Oct 20, 2022 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 20, 2022 IPO $175M Detail
Jul 13, 2021 Series B $200M 12 Detail
Oct 22, 2019 Series A $115M 5 ARCH Venture Partners
F-Prime Capital
GV
Detail

Investors

Number of Lead Investors
Number of Investors
3
12
Prime Medicine is funded by 12 investors. ARCH Venture Partners and Arrive are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
Arrive Series B
Casdin Capital Series B
Cormorant Asset Management Series B
F-Prime Capital Series B
GV Series B
Moore Strategic Ventures Series B
Newpath Management Series B
PSP Investments Series B
Redmile Group Series B

Employee Profiles

Number of Employee Profiles
10
Prime Medicine has 10 current employee profiles, including Board member Robert Nelsen
Board member
Executive
Executive
Executive
Board member